Of the 352 HCC patients, 154 (43.8%) were CK19(−)/MVI(−); 116 (33.0%), CK19(−)/MVI(+); 31 (8.8%), CK19(+)/MVI(−); and 51 (14.5%), CK19(+)/MVI(+). This evidence concerns the gene KRT19 and hepatocellular carcinoma.